Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis

Background: The advent of cystic fibrosis transmembrane conductance regulator protein (CFTR) modulators like ivacaftor have revolutionised the treatment of cystic fibrosis (CF). However, due to the plethora of variances in disease manifestations in CF, there are inherent challenges in unified respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanafin, Patrick O., Sermet-Gaudelus, Isabelle, Griese, Matthias, Kappler, Matthias, Ellemunter, Helmut, Schwarz, Carsten, Wilson, John, Tan, Marsha, Velkov, Tony, Rao, Gauri G., Schneider-Futschik, Elena K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365608/
https://www.ncbi.nlm.nih.gov/pubmed/34408649
http://dx.doi.org/10.3389/fphar.2021.577263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365608/
https://www.ncbi.nlm.nih.gov/pubmed/34408649
http://dx.doi.org/10.3389/fphar.2021.577263

Ejemplares similares